PE20091880A1 - Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias - Google Patents

Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias

Info

Publication number
PE20091880A1
PE20091880A1 PE2009000625A PE2009000625A PE20091880A1 PE 20091880 A1 PE20091880 A1 PE 20091880A1 PE 2009000625 A PE2009000625 A PE 2009000625A PE 2009000625 A PE2009000625 A PE 2009000625A PE 20091880 A1 PE20091880 A1 PE 20091880A1
Authority
PE
Peru
Prior art keywords
compounds
pirazin
heptan
triazol
pirazine
Prior art date
Application number
PE2009000625A
Other languages
English (en)
Inventor
Martin James Inglis Andrews
Gregory Louis Joseph Bar
Mark Stuart Chambers
De Poel Herve Van
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of PE20091880A1 publication Critical patent/PE20091880A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE [1.2.4]TRIAZOL[1,5-a]PIRAZINA DE FORMULA (Ia) E IMIDAZO[1,2-a]PIRAZINA DE FORMULA (Ib) DONDE W, W', Y E Y' SON CADA UNO CR2a O N, DONDE R2a ES H, ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO, HALOALQUILO(C1-C6), CN, ENTRE OTROS; X ES N O CH; L ES UN ENLACE SIMPLE, -CO-, -SO-, -SO2-, ENTRE OTROS; R1 ES H O ALQUILO(C1-C6); R3 ES ARILO O HETEROARILO OPCIONALMENTE SUSTITUIDOS; P ES UN COMPUESTO DE FORMULA (a), (b), ENTRE OTROS, DONDE R2d ES H, CICLOALQUILO(C3-C8), ALQUILO(C1-C6) OPCIONALMENTE SUSTITUIDO CON HALO, ENTRE OTROS; m1, m2 Y m3 SON CADA UNO 1 O 2. SON COMPUESTOS PREFERIDOS: 5-(8-(4-((1S,4S)-5-ISOPROPIL-2,5-DIAZABICICLO[2.2.1]HEPTAN-2-IL)FENILAMINO)-[1,2,4]TRIAZOL[1,5-a]PIRAZIN-5-IL)ISOINDOLIN-1-ONA, AMIDA DEL ACIDO 5-{8-(4-((1S,4S)-5-TER-BUTIL-2,5-DIAZABICICLO[2.2.1]HEPTAN-2-IL)FENIL-AMINO)-[1,2,4]TRIAZOL[1,5-a]PIRAZIN-5-IL}-1H-PIRAZOL-3-CARBOXILICO, 4-(8-(3-((1S,4S)-5-ISOPROPIL-2,5-DIAZABICICLO[2.2.1]HEPTAN-2-IL)FENILAMINO)IMIDAZO[1,2-a]PIRAZIN-5-IL)FURAN-2-CARBOXAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINASA 5 ACTIVADA POR PROTEINA QUINASA ACTIVADA POR MITOGENO (MAPKAPK5) SIENDO UTILES EN EL TRATAMIENTO DE ARTRITIS REUMATOIDE, ESPONDILITIS ANQUILOSANTE, OSTEOPOROSIS, ATEROSCLEROSIS
PE2009000625A 2008-05-07 2009-05-06 Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias PE20091880A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12683308P 2008-05-07 2008-05-07
US14582709P 2009-01-20 2009-01-20

Publications (1)

Publication Number Publication Date
PE20091880A1 true PE20091880A1 (es) 2009-12-28

Family

ID=40935606

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000625A PE20091880A1 (es) 2008-05-07 2009-05-06 Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias

Country Status (20)

Country Link
US (1) US8012983B2 (es)
EP (1) EP2307426A1 (es)
JP (1) JP2011519897A (es)
KR (1) KR20110028445A (es)
CN (1) CN102036997A (es)
AR (1) AR071619A1 (es)
AU (1) AU2009245731A1 (es)
BR (1) BRPI0912412A2 (es)
CA (1) CA2723745A1 (es)
CL (1) CL2009001064A1 (es)
CO (1) CO6321159A2 (es)
CR (1) CR11823A (es)
EA (1) EA201071275A1 (es)
IL (1) IL209104A0 (es)
MX (1) MX2010011994A (es)
PE (1) PE20091880A1 (es)
TW (1) TW201002716A (es)
UY (1) UY31813A (es)
WO (1) WO2009135885A1 (es)
ZA (1) ZA201008759B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201120043A (en) * 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
WO2014202458A1 (en) * 2013-06-19 2014-12-24 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CA3026784A1 (en) 2016-06-07 2017-12-14 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic pyrazine derivatives useful as shp2 inhibitors
KR20210130254A (ko) 2017-03-23 2021-10-29 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN108379583B (zh) * 2018-03-27 2021-08-17 北京大学 一种肿瘤转移药物治疗的靶标及其应用
CN113967214A (zh) * 2021-11-30 2022-01-25 广东药科大学 一种咪唑并吡嗪环丙烷甲酰胺类化合物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20020132823A1 (en) 2001-01-17 2002-09-19 Jiahuai Han Assay method
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7893058B2 (en) * 2006-05-15 2011-02-22 Janssen Pharmaceutica Nv Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases
CA2653506A1 (en) * 2006-05-31 2007-12-06 Galapagos Nv. Triazolopyrazine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
US8133895B2 (en) 2007-05-10 2012-03-13 Janssen Pharmaceutica N.V. Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases

Also Published As

Publication number Publication date
CL2009001064A1 (es) 2009-10-09
CN102036997A (zh) 2011-04-27
UY31813A (es) 2010-01-05
JP2011519897A (ja) 2011-07-14
KR20110028445A (ko) 2011-03-18
CA2723745A1 (en) 2009-11-12
TW201002716A (en) 2010-01-16
AU2009245731A1 (en) 2009-11-12
CO6321159A2 (es) 2011-09-20
US8012983B2 (en) 2011-09-06
IL209104A0 (en) 2011-01-31
WO2009135885A1 (en) 2009-11-12
US20090286798A1 (en) 2009-11-19
EP2307426A1 (en) 2011-04-13
ZA201008759B (en) 2011-08-31
CR11823A (es) 2011-03-16
BRPI0912412A2 (pt) 2016-07-26
MX2010011994A (es) 2010-11-30
AR071619A1 (es) 2010-06-30
EA201071275A1 (ru) 2011-06-30

Similar Documents

Publication Publication Date Title
PE20091880A1 (es) Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenerativas e inflamatorias
US10766902B2 (en) Wee-1 inhibiting pyrazolopyrimidinone compounds
PE20130188A1 (es) Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
PE20151764A1 (es) Derivados de pirrolo[2,3-d]pirimidina
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20121482A1 (es) Derivados de imidazopiridina como inhibidores de jak
PE20140832A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
PE20090183A1 (es) Derivados de 1-oxa-3,9-diaza-espiro-[5.5]undecan-2-ona como moduladores de ccr5
PE20080931A1 (es) Imidazopirazinas como inhibidores de proteina quinasa
PE20060727A1 (es) Antranilamidopiridinas como inhibidores de la quinasa receptora del factor de crecimiento vascular endotelial (vegf)
MY152153A (en) Macrocylic inhibitors of hepatitis c virus
PE20110944A1 (es) DERIVADOS DE PIRAZOLO[3,4-d]PIRIMIDINA COMO INHIBIDORES PDE1
PE20090984A1 (es) Inhibidores de peptido desformilasa
PE20130576A1 (es) Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
PE20140378A1 (es) Compuestos y composiciones como inhibidores de la trk
PE20140146A1 (es) Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20121431A1 (es) Derivados de pirimidina como inhbidores de la enzima cinasa ptk2
PE20141685A1 (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios
PE20141059A1 (es) Indazoles
PE20090238A1 (es) Derivados de pirazol como inhibidores de tirosinquinasas
UA102088C2 (ru) Производные n-азабициклических карбоксамидов, их получение и применение в терапии
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas

Legal Events

Date Code Title Description
FD Application declared void or lapsed